Gilead licenses remdesivir to increase global access

By The Science Advisory Board staff writers

May 13, 2020 -- Gilead Sciences has inked several agreements for the manufacture and distribution of remdesivir, which has been issued an emergency use authorization (EUA) by the U.S. Food and Drug Administration (FDA) on May 1.

Nonexclusive licensing agreements were made with Cipla, Mylan, and Hetero for remdesivir to treat COVID-19 patients. All companies will serve low- and middle-income countries, including India.

As part of their agreement, Cipla will manufacture active pharmaceutical ingredient (API) and finished product, and market the product globally under Cipla's brand name. Cipla will receive manufacturing expertise from Gilead in order to scale up commercial production. Cipla is the third largest pharmaceutical company in both India and South Africa.

In a similar agreement, Mylan will also manufacture and distribute remdesivir globally. Mylan will develop a bioequivalent version of the drug and produce its own API and finished dosage form in sterile powder lyophilized vial for intravenous infusion administration. Mylan is a global pharmaceutical company that specializes in generic, branded generic, brand name, and biosimilar drugs.

Hetero has likewise entered into an agreement with Gilead to manufacture and distribute remdesivir. The company has already developed their product in India and is working through the appropriate regulatory channels. The drug will be manufactured in Hetero's formulation facility in Hyderabad, India.

FDA issues EUA for remdesivir to treat severe COVID-19 cases
The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for the investigational antiviral drug remdesivir to be used...
Controversy hits Gilead over orphan status for COVID-19 drug
Gilead Sciences has rescinded its request for orphan drug status for an experimental drug for treating COVID-19 just two days after getting approval from...

Copyright © 2020 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Conferences
2nd Annual Cell Therapy Bioprocessing Conference
June 25-26
Boston, Massachusetts United States
BioProcess International Europe
July 13-16
Amsterdam, Noord-Holland Netherlands
Bioprocess International West
August 10-13
Santa Clara, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter